Credit: A vial of the Phase 3 Novavax coronavirus vaccine is seen ready for use in the trial at St. George's University hospital in London Wednesday, Oct. 7, 2020. Novavax Inc. said Thursday Jan. 28, 2021 that its COVID-19 vaccine appears 89% effective based on early findings from a British study and that it also seems to work — though not as well — against new mutated strains of the virus circulating in that country and South Africa. (AP Photo/Alastair Grant)

Israel to buy Novavax COVID vaccine

Tempers flare over Fairfax Co. school masks

Wandering is life or death for people with Alzheimer’s, dementia who go missing

Mix-and-match approach to COVID-19 booster shots results in better immune response

DC will offer free KN95 masks at COVID centers

Rockville firm gets FDA approval for unique at-home COVID-19 test